Drug Trial News

RSS

New cancer vaccine yields promising results in clinical study

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center of the University of Pennsylvania.

11 Apr 2018

Review identifies ethical issues in vitamin D research involving use of placebos

Since World War II, medical ethics in research studies involving human subjects have shifted significantly. Despite this important growth, ethical issues remain. Nutrition supplementation research does not have guidelines around the use of placebo groups in clinical trials, posing ethical issues.

6 Apr 2018

First-of-its-kind cancer drug effective in 93% of pediatric patients

A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of pediatric patients tested, researchers at UT Southwestern's Simmons Cancer Center announced.

30 Mar 2018

Phase I clinical trial of HIV vaccines to begin in the U.S.

A Phase I clinical trial testing the safety of vaccines that might have the potential to prevent HIV infection will begin this month at four sites in the United States, marking the latest step in a three-decade quest at UMass Medical School to harness the power of DNA vaccines in addressing a major global health threat.

28 Mar 2018

Lung transplant drug enters clinical trial after decades of research

In the culmination of decades of research at the University of Virginia Health System, doctors have begun human testing of a drug they hope will one day save many lives among lung transplant recipients.

26 Mar 2018

Bio-Optronics and Synexus announce partnership to improve global research operations

Bio-Optronics, the creator of the market-leading Clinical Conductor Clinical Trial Management System announces a new partnership with Synexus, the world’s largest site network organization.

From AES - Accelerated Enrollment Solutions 23 Mar 2018

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy) significantly increased overall survival versus treatment with sunitinib (Sutent) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center that were reported today in the New England Journal of Medicine.

22 Mar 2018

ACTA trial in AIDS patients with cryptococcal meningitis validates new therapeutic regimens

The results of the ACTA trial were presented at the 9th IAS Conference on HIV Science held in Paris from 23 to 26 July 2017. Professor Thomas Harrison and his colleagues at St George's University of London, the Institut Pasteur in Paris, Paris Descartes University (Hôpital Necker-Enfants Malades), the ANRS site in Cameroon, and the MRC sites in Malawi, Tanzania, and Zambia show in this trial that new therapeutic regimens are of benefit in HIV-infected patients with cryptococcal meningitis.

15 Mar 2018

PAREXEL and CHA collaborate to improve early phase clinical development in Korea

PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today announced an alliance with CHA Medical Group to enhance early phase clinical development in Korea.

From Parexel 14 Mar 2018

Blood-thinning drug mitigates risk of complications, death after non-cardiac surgery

Researchers in Hamilton have discovered that a blood-thinning drug, dabigatran, significantly reduces the risk of death, heart attack, stroke, and other heart or blood-vessel complications in patients who have a heart injury following major, non-cardiac surgery.

12 Mar 2018

Inhaled therapy for heart failure fails to meet either primary or secondary endpoints

Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily activity levels, severity of symptoms or quality of life in patients with a type of heart failure for which no effective treatment options currently exist, according to research presented at the American College of Cardiology's 67th Annual Scientific Session.

12 Mar 2018

PCSK9 inhibitor reduces cardiovascular events in ACS patients with high cholesterol

Among patients with persistently high cholesterol despite high-intensity statin therapy, the proprotein convertase subtilisin-kexin 9 (PCSK9) inhibitor alirocumab reduced rates of major adverse cardiovascular events by 15 percent compared with placebo, in a study presented at the American College of Cardiology's 67th Annual Scientific Session.

12 Mar 2018

Gastrointestinal hormone offers possible new treatment for NAFLD and NASH patients

Through a randomized, double-blind, placebo-controlled phase II clinical trial, researchers at University of California San Diego School of Medicine report that small doses of NGM282, a non-tumorigenic variant of an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

9 Mar 2018

One-month antibiotic regimen to prevent TB as safe, effective as nine-month therapy for HIV patients

A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with HIV, according to the results of a large international clinical trial.

6 Mar 2018

New treatment shows promise to fight against serious inflammatory disease

Still's disease is a serious orphan disease manifested by high fevers, skin and joint involvement, including paralysis, as well as damage to other organs such as the liver or spleen. It is caused by a deregulation of the immune system triggering an acute inflammatory response.

27 Feb 2018

U.S. clinical sites evaluating antibody-based therapies to prevent two common bacterial infections

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is supporting U.S. clinical sites participating in two ongoing international Phase 2 clinical trials evaluating investigational antibody-based therapies aimed at preventing potentially antibiotic-resistant infections.

23 Feb 2018

New data from VOYAGE 2 trial shows promising results for Janssen’s guselkumab treatment

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.

From J&J Innovative Medicine 22 Feb 2018

Drug Trial News

New cancer vaccine yields promising results in clinical study

Review identifies ethical issues in vitamin D research involving use of placebos

First-of-its-kind cancer drug effective in 93% of pediatric patients

Phase I clinical trial of HIV vaccines to begin in the U.S.

Lung transplant drug enters clinical trial after decades of research

Bio-Optronics and Synexus announce partnership to improve global research operations

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

ACTA trial in AIDS patients with cryptococcal meningitis validates new therapeutic regimens

PAREXEL and CHA collaborate to improve early phase clinical development in Korea

Blood-thinning drug mitigates risk of complications, death after non-cardiac surgery

Inhaled therapy for heart failure fails to meet either primary or secondary endpoints

PCSK9 inhibitor reduces cardiovascular events in ACS patients with high cholesterol

Gastrointestinal hormone offers possible new treatment for NAFLD and NASH patients

One-month antibiotic regimen to prevent TB as safe, effective as nine-month therapy for HIV patients

New treatment shows promise to fight against serious inflammatory disease

U.S. clinical sites evaluating antibody-based therapies to prevent two common bacterial infections

New data from VOYAGE 2 trial shows promising results for Janssen’s guselkumab treatment

First African child vaccinated with new typhoid conjugate vaccine

People with major depressive disorder have reduced arginine levels, study shows

Clinical trial shows safety of promising TSRI stroke drug

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News